Outsourcing

Articles

In the past, contract manufacturing organizations (CMOs) and contract development manufacturing organizations (CDMOs) have been focused most on achieving scale, reaching new clients in new geographic regions, and adding services that were previously unavailable, according to Gil Y. Roth, president of the Pharma and Biopharma Outsourcing Association. In a new report from CPhI, Roth explicates how consolidation has changed how CMOs position their services to clients and how CMOs add value to their businesses.

How CMO Consolidation is Shaping the Manufacturing Industry

Contract manufacturer PiazaBio announces services for Western Pharma companies seeking to enter the China market.

PaizaBio Introduces Aseptic Services for China Market

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Despite emergence of biologics, small-molecule APIs benefit from industry growth.

Small-Molecule API CMOs Are Thriving

Vetter plans to invest approximately 300 million Euros during the course of five years to expand drug product manufacturing and logistic services in Germany; upgrades will include an improved RABS system for aseptic processing.

Vetter Embarks on 300-Million Euro Manufacturing Expansion

Cobra Biologics and the University of Manchester announce a collaboration to improve industrial scale-up of mammalian cell bioprocessing.

Cobra Biologics Announces Scale-Up Collaboration

PharmSource forecasts slow growth in a new report on the outlook for the contract manufacturing industry.

CMO Industry Growth Unsustainable According to Report

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Suppliers indicate prices for single-use equipment are likely to increase.

CMOs Concerned With Cost of Single-Use Equipment

Recipharm will be responsible for the supply of the remaining clinical-trial material and ongoing future commercial supply of RHB-105, the lead drug candidate developed by RedHill for the treatment of Helicobacter pylori bacterial infection.

Recipharm to Manufacture RedHill Biopharma’s FDC Therapy for Helicobacter pylori Infection

Cytovance Biologics anticipates continued expansion plans following acquisition by Hepalink USA

Cytovance Biologics Acquired by Hepalink

Companies in the US will now have the opportunity to tap into Hermes Pharma’s technical expertise in effervescent and chewable tablets, instant drinks, lozenges, and orally disintegrating granules (ODGs).

Contract Manufacturing Services